GNA Biosolutions Reveals New Ultrafast PCR Platform at Medica

Published on November 13, 2017.

Groundbreaking nucleic acid detection technology using nanomaterials

DUESSELDORF, Germany, November 13 – GNA Biosolutions GmbH, a molecular technology company based in Martinsried, Germany, today announced the launch of Pharos V8, the world’s first Laser PCR® platform. Pharos V8, an ultrafast PCR instrument for in vitro research use, will be showcased at the Medica Trade Fair (Exhibition Hall 3, Booth E93) from November 13-16.


The patented technology behind the Pharos V8 platform is Laser PCR®. Laser PCR® operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR® uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.


The Pharos V8 is the company’s first platform to come on the market, with additional product launches planned over the next two years. Key features of the Pharos V8 include:

  • An open platform for universal PCR assay development
  • Ultrafast real-time nucleic acid detection in 10 minutes or less
  • Intuitive interface with easy-to-use software that can be accessed remotely

Frank Krieg-Schneider, CEO of GNA Biosolutions states, “We are excited to present our first Laser PCR® platform, the Pharos V8, at this year’s Medica.  We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”


About GNA Biosolutions:

GNA Biosolutions is a molecular technology company specializing in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences.


GNA Biosolutions develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.

GNA Biosolutions adds CEO to expand its management team

Published on July 5, 2016.

Munich, 05 July 2016 – GNA Biosolutions, Martinsried (Germany) has appointed Frank Krieg-Schneider as its Managing Director and CEO.


Frank is a senior executive in the diagnostics and life sciences industry with more than 20 years of experience in product development and commercialisation. After obtaining his PhD in molecular genetics from the University of Mainz, followed by a postdoctoral fellowship at the University Medical Centre Mannheim, Frank joined QIAGEN, a leading global provider of Life Science and Molecular Diagnostics products.


At QIAGEN, he was first instrumental in establishing the diagnostic sample preparation product range, and later in defining the strategy and product roadmap for the molecular diagnostics and point of care markets. In his former role as VP, Global Head of Strategic Alliances and OEM he successfully created new business opportunities for QIAGEN, such as the OEM business, Second Brands, and Customised Products. Frank managed independent businesses and employees across sites in Germany, Sweden and the United States. He drove revenues from zero to the high double-digit million USD range.


At GNA Biosolutions he is now expanding strategic alliances and promoting GNA’s commercialization. He will support GNA with his solid business experience, securing new OEM partnerships. This will allow the implementation of Laser PCR – GNA’s ultra-fast technology for molecular diagnostics – in selected partners’ applications and systems, in addition to GNA’s internal products.


He complements the existing management team, comprising the founders and co-Managing Directors Joachim Stehr, Federico Bürsgens and Lars Ullerich. The founders commented: “Frank is a perfect addition to our management team. He has a proven track record in building high-growth and profitable product portfolios.”  Frank Krieg-Schneider added: “I’m looking forward to break new ground with this strong team and our innovative technology, which applies the speed of light to PCR.”

Molecular diagnostics specialist GNA Biosolutions completes € 6 million (US$ 6.7m) financing round

Published on July 1, 2015.

Prepares for market entry with fast diagnostic instruments for hospital bugs


Munich (Germany), 1 July 2015 – GNA Biosolutions GmbH (GNA), a manufacturer of ultrafast pathogen diagnostic instruments, will receive fresh capital of € 6 million in a series B financing round. Founded in 2010, GNA welcomes new investors Robert Bosch Venture Capital (RBVC), SHS Gesellschaft für Beteiligungsmanagement GmbH, b-to-v Partners, and UnternehmerTUM-Fonds who are investing in its highly promising molecular diagnostics technology. The financing round was led by Robert Bosch Venture Capital. Existing shareholders include Mey Capital Matrix, KfW and the company’s founders.


Working with a laser-based PCR process, GNA facilitates reliable pathogen detection. The technology enables physicians and hospitals to diagnose bacterial diseases within minutes, with no need for time-consuming laboratory diagnostics. The specific DNA sequences for the pathogen under investigation are extracted and artificially multiplied (Polymerase Chain Reaction = PCR). The laser component of GNA’s technology is used for the necessary PCR thermo-cycling process (sample heating and cooling) and to read out results. Compared with traditional PCR diagnostics, this laser-based approach supplies results within just a few minutes. With low requirements in terms of sample preparation, it also facilitates the development of inexpensive diagnostics products.


GNA will use the funds from this financing round to bring its first product, the Pharos400 instrument, to market maturity. The Pharos400 processes samples with its integrated laser unit and allows a real-time detection and quantification of the results. Given its highly integrated diagnostics cartridges, Pharos400 will enable untrained hospital staff to quickly and easily obtain meaningful diagnoses. GNA will also work on developing tests for other hospital bugs. The company will focus above all on attracting university hospitals as its potential first customers.


Dr. Dieter Kraft, Investment Partner at Robert Bosch Venture Capital GmbH, comments: “With GNA Biosolutions, we are delighted to be supporting a company which operates at the interface between sophisticated mechatronic engineering and the growing global healthcare market, and one that has developed key innovations in this market.”


“PCR is now one of the fastest-growing areas of diagnostics. In recent years, the molecular diagnostics market has become a cornerstone for the world of medicine and beyond. GNA’s novel laser-based process enables physicians to treat patients faster, safely and more effectively– especially when it comes to time-critical diagnoses”, remarks Dr. André Zimmermann, Partner at the Tübingen-based growth financer SHS. Reinhilde Spatscheck, Managing Partner at SHS adds: “What convinced us is GNA’s innovative technological approach and the great potential this new PCR technology has for deployment. SHS is keen to invest in diagnostics applications that offer great growth potential.”


Comments Johan de Ruiter, Lead Investor at b-to-v Partners: “Multi-resistant bacteria present a significant problem in Germany, where between 400,000 and 600,000 treatment-related infections occur each year. Given the ultrafast availability of test results, the technology developed by GNA Biosolutions GmbH is particularly suited to applications in point-of-care diagnostics. Not only that, applications in other areas offer additional potential for marketing the technology.”


Andreas Unseld, Investment Manager at UnternehmerTUM Fonds, adds: “The efforts and initiatives currently underway in the political arena to improve hospital hygiene and get the problems associated with multi-resistant bacteria under control also require rapid, meaningful tests and diagnostic instruments capable of use, for example, in patient admissions. We see GNA as being ideally positioned to play a major role in the diagnostics market in future.”


In view of this financing round of great importance to GNA’s further development, the company’s management team – Drs. Lars Ullerich, Federico Bürsgens and Joachim Stehr – have issued the following statement: “We have already benefited from the business and industry expertise of this team of investors during the contract negotiation stage. With this financing round, we are now well positioned to jointly tackle the next key technological development steps and strategic decisions.”

Continue reading

GNA Biosolutions leads consortium for ultra-fast detection of Ebola

Published on February 19, 2015.

FILODIAG project for real time Laser PCR diagnosis in less than 15 min


Munich, Germany – 19 February 2015 – GNA Biosolutions GmbH (‘GNA’), a company developing ultra-fast diagnostic instruments for human pathogens, announced today the start of the FILODIAG (Filovirus Diagnostics) project for developing an ultra-fast Ebola detection system based on GNA’s novel Laser PCR technology. GNA is leading a consortium of the Mendel University in Brno (Czech Republic), the Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani” (Italy) and the Italian NGO EMERGENCY. The Project Number 115844 of this Ebola+ programme will be funded with EUR 2.3 million by the Innovative Medicines Initiative.


There is an urgent need for fast and accurate diagnostic tests in the current and any future Ebola crisis. The rapid diagnosis of Ebola Virus Disease (EVD) during early and late stage of infection is a decisive step for risk assessment and for guidance to physicians to take the necessary decisions to limit the spread of the infection, and to safely nurse the infected patients. While fast and easy-to-use tests usually rely on immuno-diagnostic approaches, they typically lack high sensitivity and specificity. The gold standard for accurate diagnostics is Real-Time PCR but this procedure requires special laboratory facilities and a long processing time of up to several hours. Aim of the FILODIAG project is to deliver a potentially multiplexed diagnostic system fast enough for point-of-need testing of incoming patients as well as at critical infrastructure checkpoints like airports by withdrawal of blood, or less invasive fluids, such as saliva or urine.


The core technology being used is based on GNA’s laser-heated nanoparticles (Laser PCR) that helps to overcome the time-limiting step of heating and cooling the reaction sample in conventional PCR reactions. GNA have revolutionized this standard procedure by inducing the necessary temperature cycles with laser-heated nanoparticles that can be heated and cooled more than a million times faster than in conventional PCR. GNA has already performed Ebola Laser PCR assays that detect 10 target copies of synthetic nucleotides, corresponding to the Ebola genome sequence, in less than 12 minutes.


Members of the Department of Chemistry and Biochemistry at Mendel University, Brno, will work on integrating the sample preparation with virus-binding magnetic particles. Leading scientist Dr. Vojtech Adam explains: “We will synthesize, characterize and modify the surfaces of nanomaterials to achieve a highly specific binding of viral proteins that will allow for a faster preparation step from patient samples.”


Project coordinator Dr. Lars Ullerich, a Managing Director of GNA, said: “We are working with our international partners to develop a highly sensitive and specific Laser PCR assay based on saliva, urine or blood for Ebola detection. Our proprietary Laser PCR with ten times faster cycles allows us to utilise the gold standard of PCR also in Ebola diagnostic. Together with a label free detection, the test results will be available in less than 15 minutes. Our Pharos400 system can already detect other highly dangerous pathogens within three minutes and a rapid, simple testing workflow will be crucial to deliver effective support in the management of Ebola outbreaks.”


Dr. Antonino Di Caro, director of microbiology, National Institute for Infectious Diseases “Lazzaro Spallanzani”, will test the device and the assay in a biosafety level 4 laboratory in advance of EMERGENCY conducting field testing in their recently established Ebola treatment centre in Sierra Leone.


The FILODIAG project is being funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115844 ( This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. IMI2 has recently launched the programme Ebola+, in which eight funded projects have been announced, including FILODIAG, and two further projects with a diagnostic focus. The FILODIAG project will present future progress on the website


IMI Logo2014-HorizPos EUflag EFPIAlogoWithoutText
Continue reading

Thank you for visiting us at Analytica 2014

Published on April 7, 2014.

Thank you to all our visitors for exciting discussions and inspiring feedback. We appreciate the opportunity to talk to our customers and to learn about their preferences.

GNA’s brand new Pharos400 instrument was presented for the first time ever at the 24th Analytica trade show in Munich (April 1st-4th, 2014). This world premiere resonated very well with the numerous visitors, who were attracted to GNA’s booth. The instrument is capable of performing PCR cycles within 3 seconds usings GNA’s proprietary Laser PCR technology. It furthermore facilitates a very robust, fluorescent-free DNA detection based on our NANOSTOVE technology.

GNA erhält den German Venture Award 2013

Published on March 13, 2013.

Das Private Equity Forum NRW e.V. veranstaltete am 7. März 2013 den German Venture Day in Duisburg. Neben Vorträgen und Diskussionsrunden zur Situation der deutschen Venture Capital-Branche wurden im Vorfeld acht Start-ups zur Vorstellung ihrer Geschäftskonzept ausgewählt. Die knapp 200 Teilnehmer der Konferenz entschieden im Anschluss in einer Abstimmung durch die Vergabe von symbolischen Geldmünzen über die Gewinner.

Die GNA Biosolutions GmbH konnte dabei das Fachpublikum überzeugen und gewann den German Venture Award 2013. Die zwei weiteren, gleichberechtigten Preisträger sind Bionic Composites GmbH, Hannover (links im Bild) und PayCash Europe S.A., Luxemburg (rechts).

GNA Biosolutions schließt Anschlussfinanzierungsrunde ab

Published on December 19, 2012.

Die GNA Biosolutions GmbH (Martinsried) gibt heute den Abschluss einer Finanzierungsrunde mit Mey Capital Matrix GmbH (München) als Lead-Investor bekannt.

Die drei Gründer und Geschäftsführer von GNA, Dr. Joachim Stehr, Dr. Federico Bürsgens und Dr. Lars Ullerich, führen mit dieser Finanzierungsrunde die Entwicklung einer neuartigen Systems zur ultraschnellen DNA-Detektion fort. Die zugrunde liegende Technologie des lokalen, optischen Heizens von Nanopartikeln erlaubt beispielsweise eine einmalig schnelle Erkennung von Pathogenen für die medizinische Diagnostik und die Biosischerheit.

Die Finanzierungsrunde schließt sich an das Seed-Investment der Mey Capital Matrix an. Finanzielle Details der Beteiligung wurden nicht bekannt gegeben. GNA wurde von INOVIS Capital und ARQIS Rechtanwälte beraten.

Weitere Informationen erhalten Sie unter

Neue Räumlichkeiten im IZB

Published on November 19, 2012.

IZB News

GNA Biosolutions ist im November 2012 in eine eigene Einheit innerhalb des IZB Martinsried (Innovations- und Gründerzentrum Biotech) umgezogen. Besuchen Sie uns ab sofort im Haus 6, 2. Obergeschoss.

Umzug nach Martinsried

Published on May 9, 2012.

IZB News 01

GNA Biosolutions GmbH, eine Ausgründung aus dem Lehrstuhl von Professor Feldmann (Institut für Photonik und Optoelektronik der LMU), ist zum 1. Mai 2012 in das Innovations- und Gründerzentrum (IZB) in Martinsried umgezogen.Die Räumlichkeiten im IZB mit entsprechenden Laboren und der gebotenen Infrastruktur bieten GNA eine ideale Voraussetzung für die weitere Entwicklung des Unternehmens.
Bitte beachten Sie unsere neue Anschrift:
Am Klopferspitz 19, 82152 Planegg/ Martinsried.

GNA Biosolutions GmbH schließt Erstrundenfinanzierung ab

Published on March 14, 2011.

Die GNA Biosolutions GmbH, ein Start-up von Wissenschaftlern der Ludwig-Maximilians-Universität München, hat den erfolgreichen Abschluss einer Erstrundenfinanzierung bekannt gegeben. Das Unternehmen möchte die Entwicklung einer DNA-Schnelldiagnostik auf Basis Laser-geheizter Nanopartikel (“Nanostove”-Verfahren) entscheidend beschleunigen.
GNA Biosolutions, im Juni 2010 durch Dr. Joachim Stehr, Dr. Federico Bürsgens und Lars Ullerich gegründet, ergänzt mit dieser Kapitalerhöhung durch einen Münchener Privatinvestor die bisherigen Förderungen aus Exist-Forschungstransfer (BMWi) und dem bayerischen Flügge-Programm.
Die neuartige DNA-Diagnostik mit ultra-schnellen Durchlaufzeiten von der Probe zum Ergebnis ermöglicht Einsatzgebiete wie die Vor-Ort-Analyse von Krankenhauskeimen oder die zeitkritische Detektion mikrobieller Kampfstoffe.
Finanzielle Details der Beteiligung wurden nicht bekannt gegeben.